Big Pharma R&D: What's the Future


Thursday, August 18, 2011 - 3:45pm - 6:30pm
Desmond Great Valley Hotel 1 Liberty Boulevard
Malvern, PA 19355
United States

A Pennsylvania Bio Leadership Panel open to all members interested in gaining insight into the hot topics in today's challenging bioscience marketplace.

Although the pharmaceutical industry’s investment in R&D has doubled in the past decade, fewer than half as many new products actually make it to market. Consequently, the business model of creating a handful of blockbuster drugs and marketing them to providers is no longer a sustainable model. As the industry responds to this new imperative, the current economic realities, patent expiration issues, the passage of U.S. biosimilars pathway, and an acceleration of mergers and acquisitions, we will see more changes by 2020 than the industry has had in a generation.

This will require the ability to adapt to new realities. The winners will be those companies that have the vision, flexibility, and courage to begin making changes now including outsourcing, streamlining operations, and maximizing their potential pipelines. But what are these changes and how can entrepreneurs and smaller companies realize growth opportunities? This panel will discuss and review those opportunities including:

What will internal R&D look like in the future for big pharma?

  • What will be outsourced?
  • How are companies’ identifying new potential compounds?
  • What are the licensing opportunities?
  • Are there device (drug delivery) opportunities?
  • Are VC funded spin-outs a reality and an option?


John Baldoni, Ph.D., Senior Vice President - Platform Technology & Science, GlaxoSmithKline

Jeff Jonas, M.D., Senior Vice President, R&D Specialty Pharmaceuticals, Shire plc

Bahija Jallal, Ph.D., Executive Vice President, Research & Development, MedImmune

Files & Links
Event Type: 
Public Health
Information Science/Computing